Will Maddox on Muck Rack

Will Maddox

Verified
Boston
As seen in: D Magazine, Fierce Biotech, The Dallas Morning News, D CEO, EIN News, health.einnews.com, NewsBreak, Fierce Healthcare, Fierce Pharma, The Top Line, fiercebiotechresearch.com, Lake Highlands Advocate Mag and
Staff Writer @FierceBiotech. Formerly of @DCEOmagazine and @Advocate_ED
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Will

Contact Will, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Vedana Therapeutics surfaces with $46M to develop next generation of migraine prevention therapies

|
By Will Maddox 
| Fierce Biotech
Vedana Therapeutics has emerged from stealth with $46 million in series A financing aimed at advancing the company’s subcutaneously delivered antibodies for migraine prevention. The financing was co-led by Westlake BioPartners and Canaan Partners and also included participation from Dawn Biopharma and Alexandria Venture Investments, according to a June 17 release.
Open in Who Shared Issue with article?

Jazz, AbCellera strike TCE discovery and development deal worth up to $792M per drug

|
By Will Maddox 
| Fierce Biotech
Jazz Pharmaceuticals is looking to bolster its oncology research bona fides via a partnership with AbCellera to discover and develop T-cell-engaging (TCE) antibodies that could result in up to $792 million in biobucks for each program that Jazz options.
Open in Who Shared Issue with article?

Merck inks $510M biobucks data generation partnership with Protillion

|
By Will Maddox 
| Fierce Biotech
AI drug design specialist Protillion Biosciences has inked a $510 million biobucks collaboration and license agreement with Merck & Co. that brings together Protillion’s platform and Merck’s drug discovery expertise. Protillion will receive an undisclosed upfront payment, with the potential to earn research, development and commercial milestones tied to the successful development of multiple therapies, according to a June 16 release.
Open in Who Shared Issue with article?
See all 2,291 licensed articles (2,318 Total)

Actions

Share this page

Get in touch with Will

Contact Will, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified